Featured Research

from universities, journals, and other organizations

Advanced Cancer Therapeutics enters phase 1 human clinical trials with first-in-class anti-cancer drug candidate

Date:
June 4, 2014
Source:
University of Louisville
Summary:
PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials, is now being studied in clinical trials for patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer. "As a researcher, it is incredibly rewarding to witness your group's studies move into clinical trials and potentially save the lives of cancer patients," one investigator said.

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced June 4 that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials. The U.S. Food and Drug Administration approved Phase 1 dose escalation study is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer.

Related Articles


PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients. The target, PFKFB3, is activated by oncogenes and the low oxygen state in cancers, stimulates glucose metabolism and is required for the growth of cancer cells as tumors in mice. PFK-158, which has been licensed by ACT from the James Graham Brown Cancer Center at the University of Louisville, inhibits the substrate binding domain of PFKFB3 causing a marked reduction in the glucose uptake and growth of multiple cancer types in mice.

PFK-158 human clinical trials began recruiting patients in May with the first clinical trial site located at the James Graham Brown Cancer Center, a part of KentuckyOne Health. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site at Georgetown University Medical Center in Washington, also in May.

According to Jason A. Chesney, M.D., Ph.D., deputy director of the Brown Cancer Center and a global thought leader and researcher in cancer metabolism, "PFK-158 is not only a first-in-class cancer drug but also the first to target glucose metabolism by inhibiting PFKFB3. This unique mechanism of action has resulted in efficacy against a broad spectrum of human cancers caused by common mutations as well as synergy with targeted agents that are FDA approved for several cancer types.

"As a researcher, it is incredibly rewarding to witness your group's studies move into clinical trials and potentially save the lives of cancer patients," Chesney said.

"This is a significant milestone for ACT and it supports our dedication to develop significant treatment advancements for cancer patients with first-in-class, potential breakthrough therapeutics like PFK-158," said Randall B. Riggs, president & CEO of ACT.


Story Source:

The above story is based on materials provided by University of Louisville. Note: Materials may be edited for content and length.


Cite This Page:

University of Louisville. "Advanced Cancer Therapeutics enters phase 1 human clinical trials with first-in-class anti-cancer drug candidate." ScienceDaily. ScienceDaily, 4 June 2014. <www.sciencedaily.com/releases/2014/06/140604105309.htm>.
University of Louisville. (2014, June 4). Advanced Cancer Therapeutics enters phase 1 human clinical trials with first-in-class anti-cancer drug candidate. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2014/06/140604105309.htm
University of Louisville. "Advanced Cancer Therapeutics enters phase 1 human clinical trials with first-in-class anti-cancer drug candidate." ScienceDaily. www.sciencedaily.com/releases/2014/06/140604105309.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins